Answers are grounded in this paper and cite their sources.
Major depressive disorder (MDD) lacks a molecular biomarker; extracellular matrix (ECM) remodelling and circadian disruption are candidate mechanisms. We pre-specified and tested three predictions about the ECM stiffness transcriptional programme: that it is altered in MDD, that it distinguishes MDD from bipolarand that it is coupled to circadian output. Discovery was in whole bloodwhole blood (GSE98793, n = 192); validation used a control brain series with recorded time of death (GSE45642) and two post-mortem cohorts (GSE53987, GSE92538). Robustness was assessed by entering estimated cell composition, batch, age, sex and anxiety comorbidity into the design matrix; independent genetic evidence came from FinnGen release 12 (59,333 cases). Blood analysis identified 1,151 differentially expressed genes, and both network strategies converged on matrix and mechanotransduction modules (odds ratio 5.58; permutation P = 0.001). Stiffness scores were elevated in MDD (P = 7.9 × 10⁻⁴). After adjustment for cellular composition, the ECM core (P = 0.020) and stiffness (P = 0.046) sets survived, whereas the broad literature-derived and mechanotransduction sets did not. In dorsolateral prefrontal cortex the programme moved oppositely, and blood–brain log-fold changes were negatively correlated. Specificity was not established (P = 0.057; pooled P = 0.27), no 24 h rhythmicity was detected, and common-variant enrichment was absent (all P > 0.18). ECM remodelling is a reproducible transcriptional signature of MDD that survives compositional adjustment, but it is not diagnosis-specific at current sample sizes, is not coupled to circadian programmes, and cannot be read from blood as a proxy for the brain.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: